Thioridazine sales to be discontinued in Canada

September 2005
Reactions Weekly;9/17/2005, Issue 1069, p2
Reports on the anticipated discontinuance of thioridazine sales in Canada on September 30, 2005. Risk factors associated with thioridazine medication; Advise of Health Canada to patients using thioridazine; Requirement needed by pharmacies to be permitted to continue dispensing thioridazine supplies.


Related Articles

  • Controlling acute and chronic schizophrenia. Rodman, Morton J. // RN;Apr78, Vol. 41 Issue 4, p75 

    Deals with drugs for controlling the manifestations of acute and chronic schizophrenia. Phenothiazine; Thioridazine.

  • Safety and Efficacy of Thioridazine as Salvage Therapy in Indian Patients with XDR-TB. Udwadia, Zarir F.; Sen, Tiyas; Pinto, Lancelot M. // Recent Patents on Anti-Infective Drug Discovery;May2011, Vol. 6 Issue 2, p88 

    New drugs are desperately needed to combat XDR-TB as effective treatment involves at least four drugs to which the patient is sensitive or has never received in the past. Most Indian patients have received almost all second line drugs and have amplified resistance to most of the available drugs....

  • Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent "As New Use". Amaral, Leonard; Molnar, Joseph // Recent Patents on Anti-Infective Drug Discovery;Jun2010, Vol. 5 Issue 2, p109 

    Mycobacterium tuberculosis that is resistant to Isoniazid (INH) and Rifampin (Rif) and hence, multi-drug resistant (MDR) has progressed to extensive drug resistant (XDR) status. XDR strains of Mycobacterium tuberculosis (XDR Mtb) are resistant, in addition to INH and Rif, to any...

  • The story of antipsychotics: Past and present. Ramachandraiah, Chaitra T.; Subramaniam, Narayana; Tancer, Manuel // Indian Journal of Psychiatry;2009, Vol. 51 Issue 4, p324 

    The article discusses the use of antipsychotic drugs in the past as well as the present. It explains the accidental discovery if the psychiatric effects of the group of phenothiazine derivatives by a team led by Paul Charpentier. It further elaborates on the research on phenothiazines and the...

  • Global Clinical Trials for the Treatment of TB with Thioridazine. Boeree, Martin J. // Recent Patents on Anti-Infective Drug Discovery;May2011, Vol. 6 Issue 2, p99 

    Current evidence shows that thioridazine (THZ) is ready for global clinical evaluation, while some of its derivatives and other efflux pump inhibitors reach the end stage of preclinical evaluation. In this paper, a clinical trial plan is described that investigates the antituberculosis potency,...

  • New Patentable Use of an Old Neuroleptic Compound Thioridazine to Combat Tuberculosis: A Gene Regulation Perspective. Dutta, Noton K.; Mazumdar, Kaushiki; Dastidar, Sujata G.; Karakousis, Petros C.; Amaral, Leonard // Recent Patents on Anti-Infective Drug Discovery;May2011, Vol. 6 Issue 2, p128 

    Use of the old antipsychotic phenothiazine thioridazine (THZ) for therapy of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) infection is now being seriously considered. It is reported that THZ primarily acts on enzymes involved in fatty acid metabolism and...

  • Endophytic fungi as models for the stereoselective biotransformation of thioridazine. Bastos Borges, Keyller; De Souza Borges, Warley; Tallarico Pupo, Mônica; Sueli Bonato, Pierina // Applied Microbiology & Biotechnology;Dec2007, Vol. 77 Issue 3, p669 

    The stereoselective kinetic biotransformation of thioridazine, a phenothiazine neuroleptic drug, by endophytic fungi was investigated. In general, the sulfur of lateral chain (position 2) or the sulfur of phenothiazinic ring (position 5) were oxidated yielding the major human metabolites...

  • thioridazine.  // Davis's Drug Guide for Nurses, 9th edition;2005, p1015 

    Presents information on the anti-psychotic agent thioridazine. Indications; Pharmacokinetics; Adverse reactions and side effects.

  • NZ MARC highlights risk of thioridazine-associated arrhythmia.  // Reactions Weekly;6/25/2005, Issue 1057, p2 

    Reports that New Zealand's Medicines Adverse Reactions Committee has reiterated its previous advice on the risk factors for thioridazine-associated arrhythmia. Facts about thioridazine; Recommendations of MARC to the patients who are receiving or about to receive thioridazine.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics